These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15011600)

  • 1. [Pharmaco-economic aspects of HIV therapy. Savings with HAART].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():80. PubMed ID: 15011600
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 3. Costs decline with HAART.
    AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187110
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study: HAART less costly than treatment for AIDS. Annual health care cost lowered by 31%.
    AIDS Alert; 2001 Feb; 16(2):26-7. PubMed ID: 15446225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic and socio-behavioural issues related to highly active antiretroviral therapies for HIV infection: the contribution of social science research].
    Moatti JP; Spire B
    Med Sci (Paris); 2003; 19(8-9):878-84. PubMed ID: 14593621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and economic efficacy of HAART: a shift from inpatient medical to outpatient pharmaceutical care for HIV/AIDS patients in Northeastern Italy.
    Tramarin A; J Postma M; Gerzeli S; Campostrini S; Starace F;
    AIDS Care; 2004 Feb; 16(2):213-8. PubMed ID: 14676019
    [No Abstract]   [Full Text] [Related]  

  • 9. [How to balance the antiretrovirus drugs and cost in China].
    Li TS
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1153-4. PubMed ID: 22882999
    [No Abstract]   [Full Text] [Related]  

  • 10. Socio-economic impact of antiretroviral treatment in HIV patients. An economic review of cost savings after introduction of HAART.
    Gonzalo T; García Goñi M; Muñoz-Fernández MA
    AIDS Rev; 2009; 11(2):79-90. PubMed ID: 19529748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The direct costs of HIV/AIDS care.
    Levy AR; James D; Johnston KM; Hogg RS; Harrigan PR; Harrigan BP; Sobolev B; Montaner JS
    Lancet Infect Dis; 2006 Mar; 6(3):171-7. PubMed ID: 16500598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncology impact of highly active antiretroviral therapy.
    Schlichemeyer R; Chambers C; Gill MJ
    J Oncol Pharm Pract; 2007 Mar; 13(1):17-25. PubMed ID: 17621563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy is only part of it.
    Mbewu A
    Bull World Health Organ; 2001; 79(12):1152. PubMed ID: 11842785
    [No Abstract]   [Full Text] [Related]  

  • 15. HAART less costly.
    AIDS Patient Care STDS; 2001 May; 15(5):289-90. PubMed ID: 11530771
    [No Abstract]   [Full Text] [Related]  

  • 16. [Assuring long-term success. Practicable therapy with fixed combination in a single tablet].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():81. PubMed ID: 12043088
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost of antiretroviral drugs and influence on prescribing policies.
    Jones R; Gazzard B
    Int J STD AIDS; 2006 Aug; 17(8):499-506. PubMed ID: 16925892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [No standard: drug holidays in HAART. Continuous or interval treatment?].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():81. PubMed ID: 15011601
    [No Abstract]   [Full Text] [Related]  

  • 19. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004.
    Donoghoe MC; Bollerup AR; Lazarus JV; Nielsen S; Matic S
    Int J Drug Policy; 2007 Aug; 18(4):271-80. PubMed ID: 17689375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence.
    Verweel G; Saavedra-Lozano J; van Rossum AM; Ramilo O; de Groot R
    Pediatr Infect Dis J; 2006 Nov; 25(11):987-94. PubMed ID: 17072119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.